Differential release of lipoteichoic and teichoic acids from Streptococcus pneumoniae as a result of exposure to beta-lactam antibiotics, rifamycins, trovafloxacin, and quinupristin-dalfopristin.
about
Bioengineering of the model lantibiotic nisinPrevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitisLipoteichoic acid inhibits interleukin-2 (IL-2) function by direct binding to IL-2.Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity.Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis.In vivo activity of nisin A and nisin V against Listeria monocytogenes in mice.Surface glycosaminoglycans protect eukaryotic cells against membrane-driven peptide bacteriocins.Streptococcus pneumoniae Infection aggravates experimental autoimmune encephalomyelitis via Toll-like receptor 2.Differences in clinical manifestation of Streptococcus pneumoniae infection are not correlated with in vitro production and release of the virulence factors pneumolysin and lipoteichoic and teichoic acids.Lipid II as a target for antibiotics.Biomedical applications of nisin.Systemic infections in multiple sclerosis and experimental autoimmune encephalomyelitis.Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegenerationMode of action and structure-activity relationship studies of geobacillin I.Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance.'Bac' to the future: bioengineering lantibiotics for designer purposes.Bacterial meningitis: new therapeutic approaches.Advances in the arsenal of tools available enabling the discovery of novel lantibiotics with therapeutic potential.Bacterial meningitis: an update of new treatment options.Anaerobes as Sources of Bioactive Compounds and Health Promoting Tools.Rethinking the composition of a rational antibiotic arsenal for the 21st century.Bacteriocin-producing oral streptococci and inhibition of respiratory pathogens.Gemifloxacin is effective in experimental pneumococcal meningitisActivity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin.Moxifloxacin in the therapy of experimental pneumococcal meningitis.Rifampin followed by ceftriaxone for experimental meningitis decreases lipoteichoic acid concentrations in cerebrospinal fluid and reduces neuronal damage in comparison to ceftriaxone alone.Development of Class IIa Bacteriocins as Therapeutic Agents.Strategies to increase the activity of microglia as efficient protectors of the brain against infections.Lipoteichoic acid is important in innate immune responses to gram-positive bacteria.Synthesis of nisin AB dicarba analogs using ring-closing metathesis: influence of sp(3) versus sp(2) hybridization of the α-carbon atom of residues dehydrobutyrine-2 and dehydroalanine-5 on the lipid II binding affinity.Comparison of lipoteichoic acid from different serotypes of Streptococcus pneumoniae.Beta-lactam antibiotic-induced release of lipoteichoic acid from Staphylococcus aureus leads to activation of neutrophil granulocytes.Antibiotic-induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: a review.Improving the attrition rate of Lanthipeptide discovery for commercial applications.
P2860
Q28087616-D1584DD4-ECC1-4715-A1DE-7400008B7BA1Q28757559-6CABFEBD-8B12-4316-B8EA-779D4DE2598FQ33999489-73A1D71B-0FAD-4838-A577-4E2D9C459F3FQ34041860-651304DC-AD79-41C3-B5FE-C5B89409A66AQ34487226-E18977DE-5A96-4663-A819-750604A60680Q34572089-60DF68C0-7C9F-4058-9DE1-4C038D742FEBQ34923184-9CC5E35F-0C17-4A3B-A578-386AC4BAEE39Q34975805-697D784F-F1FF-4395-8DFC-074B255784B7Q35717365-B02CA236-9F3C-4E6A-8077-27AC4F2185B8Q36419233-12D56EF5-DFFC-436A-9553-10BDA3C6E776Q36900890-48878CD0-2EA6-4D70-839C-10654424A471Q36964570-0FC8CDDF-73C8-442B-B0CB-2F56CA88651AQ37270004-C686CEA9-9915-4FFA-BBC0-0B1708D55FF0Q37732541-CE745C0D-94EB-4786-9EA4-02B9640450B4Q38009935-F53071E1-D625-4632-8F6A-007A4A879B32Q38062005-7CCDEB7F-1D01-44EA-BE66-1F45B249B743Q38145360-50391E55-21CE-4C64-811D-12943A77F996Q38177305-941D8E73-FBFC-452A-A162-19CC27A484D6Q38570487-EC13AE90-C4B8-44C3-89C6-5B4244E4A95BQ38901723-041D7066-E059-45BA-9F2A-9D8B2CB340BBQ39383695-3B950CBF-ECAD-46F2-9BE5-D0367C893411Q39412693-F73F43E0-8FBE-49D3-BE65-9DB6651D9858Q39473262-C4E6CB11-9830-4E90-A461-5BCAB0EBDBD0Q39477892-28FD2B9F-065B-4835-AE1B-A5E27879B1A2Q39557705-D57732A7-3EE7-44F1-A410-D1E9C49636E9Q39743417-CBF3BFDE-364B-40D0-9AA1-C55720646D65Q39751193-880E04A8-98EC-48F4-9DA8-978D38DB27D2Q39924370-53D1774B-0A5C-41A3-91E6-C6C16A76E20BQ40063735-DEC8B862-F5C4-4C06-B09C-972BCD2FC8A3Q40977609-6E3F1947-CFEE-4A32-AB41-E2AF4ECD63DDQ42596969-4262BB11-EBDD-4F36-8E61-8502D38DDF0EQ42870941-05FA40DB-A7FF-408B-9C27-DFAF6F54D9C2Q45137694-1771D026-5C64-409B-AF6A-D515D77BCC1AQ47383314-24829C63-C024-47DD-BE02-06CC71EB7CB0
P2860
Differential release of lipoteichoic and teichoic acids from Streptococcus pneumoniae as a result of exposure to beta-lactam antibiotics, rifamycins, trovafloxacin, and quinupristin-dalfopristin.
description
1998 nî lūn-bûn
@nan
1998 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Differential release of lipote ...... and quinupristin-dalfopristin.
@ast
Differential release of lipote ...... and quinupristin-dalfopristin.
@en
type
label
Differential release of lipote ...... and quinupristin-dalfopristin.
@ast
Differential release of lipote ...... and quinupristin-dalfopristin.
@en
prefLabel
Differential release of lipote ...... and quinupristin-dalfopristin.
@ast
Differential release of lipote ...... and quinupristin-dalfopristin.
@en
P2093
P2860
P356
P1476
Differential release of lipote ...... and quinupristin-dalfopristin.
@en
P2093
P2860
P304
P356
10.1093/JAC/42.2.277
P407
P577
1998-02-01T00:00:00Z